Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MYC | P01106 | 1/20 | 0.49 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | CFTR | P13569 | 1/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28989185 | 0.76 | MYC (0.50) | KMT2AMEN1POLBSMN1; SMN2MYC | |
| SCHEMBL28989191 | 0.75 | MYC (0.49) | KMT2AMEN1POLBSMN1; SMN2MYC | |
| SCHEMBL22904105 | 0.75 | CRBN (0.42) | KMT2AMEN1POLBSMN1; SMN2CRBN | |
| SCHEMBL22904247 | 0.74 | ALDH1A1 (0.51) | SMN1; SMN2LMNAALDH1A1L3MBTL1MAPT | |
| SCHEMBL22904564 | 0.74 | ADRB1 (0.47) | KMT2AMEN1POLBSMN1; SMN2CRBN | |
| SCHEMBL23708768 | 0.74 | NPC1 (0.60) | KMT2AMEN1POLBSMN1; SMN2MYC | |
| SCHEMBL5745275 | 0.74 | BRPF1 (0.53) | KMT2AMEN1POLBSMN1; SMN2MYC | |
| SCHEMBL112024 | 0.74 | ADRB1 (0.55) | KMT2AMEN1SMN1; SMN2MYCLMNA | |
| SCHEMBL7715935 | 0.74 | MYC (0.54) | KMT2AMEN1POLBSMN1; SMN2MYC | |
| SCHEMBL29232403 | 0.74 | MYC (0.54) | KMT2AMEN1POLBSMN1; SMN2MYC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021011631-A1 | FUSED-GLUTARIMIDE CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
| US-20160331734-A1 | SUBSTITUTED N-ARYL PYRIDINONES | AUSPEX PHARMACEUTICALS, INC. | 2016-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160331734-A1 | SUBSTITUTED N-ARYL PYRIDINONES | COL1A1, COL2A1, COLGALT1 | KMT2A 4095/4885MEN1 4796/4885POLB 1402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.